Grade 3 or 4 adverse events occurring in at least 5% of patients for the entire population by treatment arm
| Grade 3 or 4 adverse event . | Arm A, concurrent R-EPOCH (n = 51), no. (%) . | Arm B, sequential EPOCH → R (n = 55), no. (%) . |
|---|---|---|
| Neutropenia | 22 (43) | 22 (40) |
| Anemia | 10 (22) | 7 (13) |
| Thrombocytopenia | 4 (8) | 9 (16) |
| Febrile neutropenia | 8 (16) | 8 (15) |
| Infection | 14 (27) | 16 (29) |
| Neuropathy | 0 | 3 (5) |
| Mucositis | 1 (2) | 4 (7) |
| Grade 3 or 4 adverse event . | Arm A, concurrent R-EPOCH (n = 51), no. (%) . | Arm B, sequential EPOCH → R (n = 55), no. (%) . |
|---|---|---|
| Neutropenia | 22 (43) | 22 (40) |
| Anemia | 10 (22) | 7 (13) |
| Thrombocytopenia | 4 (8) | 9 (16) |
| Febrile neutropenia | 8 (16) | 8 (15) |
| Infection | 14 (27) | 16 (29) |
| Neuropathy | 0 | 3 (5) |
| Mucositis | 1 (2) | 4 (7) |